37results about How to "Improve reconstitution performance" patented technology

The invention relates to a levocarnitine composition for injection and a preparation method of the levocarnitine composition; the levocarnitine composition is lyophilized powder containing levocarnitine and mannitol, wherein the weight ratio of the levocarnitine to the mannitol is 1:(0.75-1.25); the average particle diameter of the lyophilized powder is 90-130 nm, and the porosity is 94-98%. The preparation method comprises the steps of: 1) preparing: weighing levocarnitine and mannitol, putting the levocarnitine and the mannitol in a preparing tank, adding injection water, agitating to enable the levocarnitine and the mannitol to be completely dissolved and uniformly mixing, regulating the pH to 5.7-6.3 through a 0.1mol/L hydrochloric acid solution; 2) decarburizing and sterile filtering; 3) sterile packaging; 4) vacuum freeze drying to obtain the levocarnitine composition . The levocarnitine composition has the advantages of simple preparation, advanced technique, uniform quality, excellent stability, better redissolution capability and clinic medicine application safety.

The present invention relates to the field of skin repair, and provides a skin external composition. The skin external composition comprises mesenchymal stem cell exosome lyophilized powder, wherein the lyophilized powder contains at least 25.0-35.0 ng/g of fibronectin, 5.0-14.5 ng/g of a vascular endothelial growth factor, 5.5-15.5 ng/g of a fibroblast growth factor, 5.0-10.0 ng/g of an epithelial cell growth factor, 25.0-30.0 ng/g of a hepatocyte growth factor, 7.5-17.5 ng/g of a transforming growth factor, 0.5-5 ng/g of 1-sphingosine phosphate, and 0.5-5 ng/g of ceramide-1-phosphoric acid.The skin external composition provided by the invention comprises the mesenchymal stem cell exosome lyophilized powder having a repairing effect on the skin, does not contain medium components or cellular components, avoids damage to the human body and the skin by adding a cytotoxic substance and avoids the potential hazard of skin allergies. The product is more stable after being prepared as lyophilized powder so as to exert biological activity for a longer period of time.

The invention relates to a clindamycin phosphate composition for injection. The composition is freeze-dried powder which consists of clindamycin phosphate and sodium hydroxide, wherein the weight ratio of the clindamycin phosphate to the sodium hydroxide is (24-26):1; the average grain diameter of the freeze-dried powder is 70-130nm; and the porosity is 92-98 percent. A preparation method of the composition comprises the following steps of: (1) preparing: weighing the clindamycin phosphate and the sodium hydroxide, filling in a preparation tank, adding water for injection, stirring to fully dissolve the clindamycin phosphate and the sodium hydroxide and uniformly mixing; (2) decarbonizing and performing sterile filtration; (3) performing sterile subpackaging; and (4) freeze-drying under vacuum. The composition has the advantages of simple formula, advanced process, uniform quality and superior stability and meanwhile has better redissolving performance and clinical medication safety.

The invention discloses zirconium chelate-modified compound alkali soluble emulsion and high-resolubility waterborne ink prepared based on the same. Epoxy propane, diisocyanate, acrylic monomers and corresponding functional monomers are taken as raw materials, high-molecular alkali soluble emulsion with similar bimodal particle size distribution is synthesized by adopting suspension polymerization and ring-opening polymerization principles and serves as a novel waterborne ink link material; the emulsion is high in solid content and high in resolubility, and has water-resistant performance; zirconium chelate is added in a preparation process of the emulsion, and central atoms of zirconium chelate are cross-linked with hydrophilic groups on high-molecular resin, so that water-resistant performance of an emulsion system is further improved under high resolubility; the obtained emulsion is mixed with pigment, an assistant, a co-solvent and the like, the high-resolubility waterborne ink is obtained with a technological method of ball milling and mixing, and the ink is high in resolubility, strong in water resistance and moderate in viscosity and overcomes shortcomings of low resolubility, poor water resistance and the like of existing waterborne ink.

The invention discloses an octreotide acetate freeze-dried powder injection for injection, which comprises octreotide acetate, mannitol, trehalose, L-cysteine, lactic acid and sodium bicarbonate, wherein the mass ration of the octreotide acetate to the mannitol to the trehalose to the L-cysteine is 1 to (200 to250) to (50 to 100) to (5 to 10). According to the octreotide acetate freeze-dried powder injection for injection provided by the invention, by adding the mannitol, the trehalose and the L-cysteine with a certain ratio to combine a freeze-drying protective additive, the stability of octreotide acetate is greatly improved, and the storage time of the octreotide acetate is prolonged.

The invention relates to potassium magnesium aspartate freeze-dried powder preparation for injection. The potassium magnesium aspartate freeze-dried powder preparation for injection is prepared from the following materials in parts by weight: 400-600 parts of potassium aspartate, 400-600 parts of magnesium aspartate and 320-480 parts of lactose. The freeze-dried powder preparation disclosed by the invention has the advantages of being simple in prescription and scientific and reasonable in preparation method, so that the freeze-dried product is more fluffy and porous, thereby remarkably improving the re-dissolution of the freeze-dried powder preparation during the clinical use process; meanwhile, the stability of the preparation is further improved on the condition of low auxiliary material dosage and less categories, so that the medication safety of the patient is ensured.

The invention discloses doxorubicin hydrochloride pharmaceutical composition and a preparation method thereof. The composition contains doxorubicin hydrochloride and mannitol. The preparation method comprises the following steps: 1), preparation: the ambroxol hydrochloride and the mannitol at a weight ratio of 1:(1-20) are placed into a preparation tank, water for injection is added, and the mixture is stirred until the mixture is completely dissolved and uniformly mixed 2), sterile filtration, subpackaging and half stoppering; and 3), vacuum freeze drying, thereby obtaining the composition. The composition and the preparation method have the advantages that the formula is simple, the technology is advanced, the quality is uniform and stable, moisture drying is thorough, and the redissolution performance is better.

The invention relates to a compound lumbricus extract, and a preparation process and a composition thereof. The compound lumbricus extract comprises, by weight, 25 parts of a fresh product of lumbricus, 3.5 parts of Ligusticum wallichii, 3 parts of Radix Astragali and 2 parts of achyranthes root. The preparation process comprises the following steps: 1) preparing lumbricus powder, that is, taking 25 parts of the fresh product of lumbricus, cleaning and draining the fresh product of lumbricus, adding water with a weight equal to that of the fresh product of lumbricus, carrying out stirring and homogenization at a temperature of 37 DEG C, carrying out centrifugation, taking a supernatant for membrane filtration, condensing obtained filtrate, and carrying out freeze drying on obtained concentrate; 2) preparing extracts of Ligusticum wallichii, achyranthes root and Radix Astragali, that is, taking Ligusticum wallichii, achyranthes root and Radix Astragali by above-mentioned corresponding weight percentage, adding 6 to 10 times of an ethanol solution with a concentration of 50 to 90%, carrying out reflux extraction twice, each lasting 2 hours, carrying out filtration, merging alcohol liquid, recovering the alcohol liquid, condensing the alcohol liquid until relative density of the alcohol liquid is about 1.1 to 1.5, and drying the alcohol liquid; 3) preparing the compound lumbricus extract, that is, uniformly mixing the lumbricus powder prepared in step 1) and extracts of Ligusticum wallichii, achyranthes root and Radix Astragali prepared in step 2).

The present invention discloses a mulberry leaf black tea solid beverage preparation method and processing equipment. The mulberry leaf black tea solid beverage preparation method mainly comprises the following processing steps of freeze drying, mechanical crushing, constant temperature extraction, low temperature concentration, secondary freeze drying, blending and mixing, wet granulation, and drying and packaging. The processing equipment comprises a processing box, a plurality of supports are fixed to the bottom of the processing box, a plurality of feeding barrels are fixed to the upper end of the processing box, a plurality of feeding openings correspondingly communicating with the feeding barrels are formed in the top of the processing box in a penetrating mode, and a plurality of pre-grinding mechanisms are arranged at the inner top of the processing box. The mulberry leaf black tea solid beverage preparation method has the advantages that the prepared mulberry leaf black tea solid beverage is good in taste, good in resolubility, small in size, convenient to carry, instant to drink and capable of being drunk after being brewed with warm water, the condition restriction problem that mulberry leaf black tea can be drunk after being brewed with hot water is solved, and the mulberry leaf black tea solid beverage can serve as an auxiliary hypoglycemic dietary therapy product to be used for daily postprandial blood sugar control of diabetics.

The invention discloses methylphenidate hydrochloride pharmaceutical composition and a preparation method thereof. The composition contains methylphenidate hydrochloride and mannitol. The preparation method comprises the following steps: 1), preparation is performed: ambroxol hydrochloride and mannitol are placed into a preparation tank in a weight ratio of 1:(1-20), water for injection is added, and the mixture is stirred until complete dissolution and uniform mixing are achieved; 2), sterile filtration, subpackaging and half stoppering are performed; and 3), vacuum freeze drying is performed to obtain a product. The composition and the preparation method have the advantages that the formula is simple, the technology is advanced, the quality is uniform and stable, moisture drying is thorough, and the redissolution performance is better.